Lyell Immunopharma, Inc.
Lyell develops next-generation CAR T-cell therapies for hematologic malignancies and solid tumors.
SCHEDULE 13G/ANov 10Latest SEC filing
Nov 4Latest story
Lyell develops next-generation CAR T-cell therapies for hematologic malignancies and solid tumors.
November 2026
September 2026
August 2026